[go: up one dir, main page]

WO2009138494A3 - Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors - Google Patents

Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors Download PDF

Info

Publication number
WO2009138494A3
WO2009138494A3 PCT/EP2009/055926 EP2009055926W WO2009138494A3 WO 2009138494 A3 WO2009138494 A3 WO 2009138494A3 EP 2009055926 W EP2009055926 W EP 2009055926W WO 2009138494 A3 WO2009138494 A3 WO 2009138494A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
toll
amino acid
acid sequences
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/055926
Other languages
French (fr)
Other versions
WO2009138494A2 (en
Inventor
Peter Vanlandschoot
Cornelis Theodorus Verrips
Anna Hultberg
Bram Maassen
Rudi Beyaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of WO2009138494A2 publication Critical patent/WO2009138494A2/en
Publication of WO2009138494A3 publication Critical patent/WO2009138494A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to amino acid sequences that are directed against and/or that can specifically bind to Toll-like receptors, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
PCT/EP2009/055926 2008-05-15 2009-05-15 Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors Ceased WO2009138494A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5351708P 2008-05-15 2008-05-15
US61/053,517 2008-05-15
US7848608P 2008-07-07 2008-07-07
US61/078,486 2008-07-07

Publications (2)

Publication Number Publication Date
WO2009138494A2 WO2009138494A2 (en) 2009-11-19
WO2009138494A3 true WO2009138494A3 (en) 2010-02-25

Family

ID=41050975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/055926 Ceased WO2009138494A2 (en) 2008-05-15 2009-05-15 Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors

Country Status (1)

Country Link
WO (1) WO2009138494A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2721378T3 (en) 2011-01-10 2019-07-31 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
CN104540851B (en) 2012-03-29 2017-09-15 诺夫免疫股份有限公司 Anti-TLR4 antibodies and uses thereof
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
CA2928317A1 (en) 2013-10-22 2015-04-30 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
CA2932787A1 (en) 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
EP3702369A1 (en) 2014-05-16 2020-09-02 Ablynx NV Immunoglobulin variable domains
US20230416356A1 (en) * 2020-11-23 2023-12-28 Scout Bio, Inc. Antigen-binding molecules and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Data sheet for Anti-hTLR1-IgG Purified monoclonal IgG antibody to human TLR1 Catalog # mabg-htlr1; Clone: H2G2 Isotype: Mouse IgG1", XP002545580, Retrieved from the Internet <URL:http://www.invivogen.com/PDF/Anti-hTLR1_IgG_TDS_08L10MM.pdf> *
ABNOVA: "TLR1 polyclonal Ab; CatNr: PAB0215", XP002545583, Retrieved from the Internet <URL:http://www.abnova.com/PDFServer/outputs/PAB0215.pdf> *
AFFINITY PURIFIED ANTIHUMAN TOLLLIKE RECEPTOR 1 (CD281, TLR1, TLR1): "eBioscience - Catalog Number: 14-9911 - Clone: GD2.F4", XP002545503, Retrieved from the Internet <URL:http://www.ebioscience.com/ebioscience/specs/pdf/antibody_14/14-9911.pdf> *
DUNNE AISLING ET AL: "Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 17 OCT 2003, vol. 278, no. 42, 17 October 2003 (2003-10-17), pages 41443 - 41451, XP002545585, ISSN: 0021-9258 *
KANZLER HOLGER ET AL: "Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.", NATURE MEDICINE MAY 2007, vol. 13, no. 5, May 2007 (2007-05-01), pages 552 - 559, XP002545584, ISSN: 1078-8956 *
OMUETI KATHERINE O ET AL: "The polymorphism P315L of human toll-like receptor 1 impairs innate immune sensing of microbial cell wall components.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAY 2007, vol. 178, no. 10, 15 May 2007 (2007-05-15), pages 6387 - 6394, XP002545579, ISSN: 0022-1767 *
SANDOR F ET AL: "Importance of extra- and intracellular domains of TLR1 and TLR2 in NFkappaB signaling", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 162, no. 6, 15 September 2003 (2003-09-15), pages 1099 - 1110, XP002317653, ISSN: 0021-9525 *
SANTA CRUZ BIOTECHNOLOGY, INC.: "Datasheet: TLR1 (C-18): sc-8688", XP002545582, Retrieved from the Internet <URL:http://datasheets.scbt.com/sc-8688.pdf> *
SANTA CRUZ BIOTECHNOLOGY, INC.: "Datasheet: TLR1 (N-20): sc-8687", XP002545581, Retrieved from the Internet <URL:http://datasheets.scbt.com/sc-8687.pdf> *
XU Y ET AL: "Structural basis for signal transduction by the Toll/interleukin-1 receptor domains.", NATURE 2 NOV 2000, vol. 408, no. 6808, 2 November 2000 (2000-11-02), pages 111 - 115, XP002545578, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2009138494A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2009068625A3 (en) Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009155001A3 (en) Wnt protein signalling inhibitors
MX2010008688A (en) Engineered anti-tslpr antibodies.
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2012058393A3 (en) Dkk1 antibodies and methods of use
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EP2373692A4 (en) Dual variable domain immunoglobulins and uses thereof
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
WO2009129246A3 (en) Compositions and methods for preparing and using same
TN2012000393A1 (en) Agonist dr5 binding polypeptides
WO2010132370A3 (en) Soluble tlt-1 for the treatment and diagnosis of sepsis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09745826

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09745826

Country of ref document: EP

Kind code of ref document: A2